Loading...

FITC anti-mouse CD4 Antibody

Pricing & Availability
Clone
GK1.5 (See other available formats)
Regulatory Status
RUO
Other Names
L3T4, T4
Isotype
Rat IgG2b, κ
Ave. Rating
Submit a Review
Product Citations
publications
GK1.5_FITC_102110
C57BL/6 mouse splenocytes were stained with CD4 (clone GK1.5) FITC (filled histogram) or rat IgG2b, κ FITC isotype control (open histogram).
  • GK1.5_FITC_102110
    C57BL/6 mouse splenocytes were stained with CD4 (clone GK1.5) FITC (filled histogram) or rat IgG2b, κ FITC isotype control (open histogram).
Compare all formats See FITC spectral data
Cat # Size Price Quantity Check Availability Save
100405 50 µg 24€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100406 500 µg 80€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD4 is a 55 kD protein also known as L3T4 or T4. It is a member of the Ig superfamily, primarily expressed on most thymocytes, a subset of T cells, and weakly on macrophages and dendritic cells. It acts as a coreceptor with the TCR during T cell activation and thymic differentiation by binding MHC class II and associating with the protein tyrosin kinase, lck.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Mouse CTL clone V4
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with FITC under optimal conditions.
Concentration
0.5 mg/ml
Storage & Handling
The CD4 antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Application Notes

Additional reported applications (for the relevant formats) include: blocking of CD4+ T cell activation1,4,11, thymocyte costimulation3, in vitro and in vivo depletion2,5-8, blocking of egg-sperm cell adhesion1,4, immunohistochemical staining of acetone-fixed frozen sections9,10, immunoprecipitation1,2, and spatial biology (IBEX)12,13. The GK1.5 antibody is able to block CD4 mediated cell adhesion and T cell activation. Binding of GK1.5 antibody to CD4 T cells can be blocked by RM4-5 antibody, but not RM4-4 antibody. For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 100442) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin < 0.01 EU/µg).

Application References
  1. Dialynas DP, et al. 1983. J. Immunol. 131:2445. (Block, IP)
  2. Dialynas DP, et al. 1983. Immunol. Rev. 74:29. (IP, Deplete)
  3. Wu L, et al. 1991. J. Exp. Med. 174:1617. (Costim)
  4. Godfrey DI, et al. 1994. J. Immunol. 152:4783. (Block)
  5. Gavett SH, et al. 1994. Am. J. Respir. Cell. Mol. Biol. 10:587. (Deplete)
  6. Schuyler M, et al. 1994. Am. J. Respir. Crit. Care Med. 149:1286. (Deplete)
  7. Ghobrial RR, et al. 1989. Clin. Immunol. Immunopathol. 52:486. (Deplete)
  8. Israelski DM, et al. 1989. J. Immunol. 142:954. (Deplete)
  9. Zheng B, et al. 1996. J. Exp. Med. 184:1083. (IHC)
  10. Frei K, et al. 1997. J. Exp. Med. 185:2177. (IHC)
  11. Felix NJ, et al. 2007. Nat. Immunol. 8:388. (Block)
  12. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  13. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Wang X, et al. 2019. Cell Res. 29:787. PubMed
  2. Chuang H, et al. 2014. Nat Commun. 5:4602. PubMed
  3. Djokić V, et al. 2019. Front Immunol. 9:2891. PubMed
  4. Katsumura KR, et al. 2018. Proc Natl Acad Sci U S A. 115:E10109. PubMed
  5. Valanparambil RM, et al. 2017. PLoS Pathog. 13:e1006647. PubMed
  6. Chang YS, et al. 2020. Int J Mol Sci. 21:00. PubMed
  7. Xue G, et al. 2021. Cancer Cell. 39:1610. PubMed
  8. Mills EL, et al. 2022. Cell Metab. 34:140. PubMed
  9. Li X, et al. 2022. J Clin Invest. 132: . PubMed
  10. Wu R, et al. 2022. J Dermatol. 49:432. PubMed
  11. Mi Z, et al. 2021. Vaccines (Basel). 10: . PubMed
  12. Corral D, et al. 2022. Cell Rep. 39:110715. PubMed
  13. Lu R, et al. 2022. Scand J Immunol. 96:e13177. PubMed
  14. Shen Z, et al. 2022. EBioMedicine. 85:104285. PubMed
  15. Balood M, et al. 2022. Nature. 611:405. PubMed
  16. Zhu M, et al. 2022. Front Immunol. 13:1019248. PubMed
  17. Zhang Z, et al. 2022. Integr Cancer Ther. 21:15347354221138534. PubMed
  18. Wei M, et al. 2022. Front Immunol. 13:1017574. PubMed
  19. Wang H, et al. 2022. J Nanobiotechnology. 20:513. PubMed
  20. Chen C, et al. 2022. J Neuroinflammation. 19:315. PubMed
  21. Qin S, et al. 2023. Acta Pharm Sin B. :. PubMed
  22. Merk VM, et al. 2023. Genes Immun. 24:52. PubMed
  23. Meng S, et al. 2023. Stem Cell Investig. 10:2. PubMed
  24. Sun Y, et al. 2023. Cell Mol Life Sci. 80:63. PubMed
  25. Hajjar S, et al. 2022. Cell Death Differ. 29:585. PubMed
  26. Sylvester MA, et al. 2022. Am J Physiol Renal Physiol. 322:F245. PubMed
  27. Zander R, et al. 2022. Immunity. 55:475. PubMed
  28. Qiu Z, et al. 2022. J Exp Med. 219:. PubMed
  29. Lin J, et al. 2022. Adv Sci (Weinh). 9:e2202633. PubMed
  30. Hamdi L, et al. 2022. Ann Clin Transl Neurol. 9:1792. PubMed
  31. Deák P, et al. 2022. Cell Rep. 41:111563. PubMed
  32. Zhu C, et al. 2022. Chemotherapy. 67:211. PubMed
  33. Pan Y, et al. 2023. Adv Sci (Weinh). 10:e2206792. PubMed
  34. Wilson NG, et al. 2023. iScience. 26:105991. PubMed
  35. Zhuang WR, et al. 2023. Nat Commun. 14:1675. PubMed
  36. Mackin S, et al. 2023. Nat Microbiol. 8:569. PubMed
  37. Shi Y, et al. 2023. Nat Commun. 14:1884. PubMed
  38. Liu H, et al. 2023. Breast Cancer Res. 25:43. PubMed
  39. Fu S, et al. 2023. Nat Commun. 14:2248. PubMed
  40. Fiedler T, et al. 2023. J Neuroinflammation. 20:100. PubMed
  41. Yu L, et al. 2023. Front Oncol. 13:1174713. PubMed
  42. Wang Y, et al. 2023. iScience. 26:106630. PubMed
  43. Vereertbrugghen A, et al. 2023. J Neuroinflammation. 20:120. PubMed
  44. Peymanfar Y, et al. 2023. Int J Mol Sci. 24:. PubMed
  45. Wang X, et al. 2023. Nat Commun. 14:3440. PubMed
  46. Yao RQ, et al. 2023. Mil Med Res. 10:27. PubMed
  47. Iwanami N, et al. 2023. Nat Commun. 14:3645. PubMed
  48. Solvay M, et al. 2023. J Immunother Cancer. 11:. PubMed
  49. Wang Z, et al. 2023. Sci Adv. 9:eabo4100. PubMed
  50. Zelenka T, et al. 2022. Nat Commun. 13:6954. PubMed
  51. Zhao J, et al. 2021. Emerg Microbes Infect. 10:913. PubMed
  52. Liu J, et al. 2021. Front Immunol. 12:747730. PubMed
  53. Su Y, et al. 2022. J Hematol Oncol. 15:99. PubMed
  54. Li Z, et al. 2022. Nat Commun. 13:1845. PubMed
  55. Wu N, et al. 2020. Cell Rep. 30:1129. PubMed
  56. Alissafi T, et al. 2018. J Clin Invest. 128:3840. PubMed
  57. Rosenkranz SC, et al. 2021. eLife. 10:00. PubMed
  58. Furuta Y, et al. 2017. PLoS One. 12(2):e0172509. PubMed
  59. Yang Z, et al. 2022. J Immunother Cancer. 10:. PubMed
  60. Li Q, et al. 2022. Cell Rep. 40:111308. PubMed
  61. Schönberger K, et al. 2022. Cell Stem Cell. 29:131. PubMed
  62. He R, et al. 2021. J Immunol. 206:2353. PubMed
  63. Ma J, et al. 2020. Adv Sci (Weinh). 7:2000609. PubMed
  64. Fan L, et al. 2021. Cancers (Basel). 13:. PubMed
  65. Sega E, et al. 2008. Int J Radiat Oncol Biol Phys. 71:559. PubMed
  66. Lua Y, et al. 2012. Mol Immunol. 52:229. PubMed
  67. Zasłona Z, et al. 2014. J Immunol. 193:4245. PubMed
  68. Aguilera T, et al. 2016. Nat Commun. 7:13898. PubMed
  69. Saleh MM, et al. 2019. Cell Host Microbe. 25:756. PubMed
  70. Yang F, et al. 2021. Front Microbiol. 11:512581. PubMed
  71. Toomer G, et al. 2022. Viruses. 14:. PubMed
  72. Luo R, et al. 2021. Theranostics. 11:117. PubMed
  73. Xu ZH, et al. 2021. Mediators Inflamm. 2021:8856326. PubMed
  74. Liang S, et al. 2022. Acta Pharm Sin B. 12:2494. PubMed
  75. Jiang W, et al. 2022. Front Immunol. 13:878832. PubMed
  76. Periasamy S, et al. 2017. Nat Commun. 8:15564. PubMed
  77. Pobezinskaya EL et al. 2019. Front Immunol. 1.079861111 . PubMed
  78. Choi H et al. 2019. Cell Rep. 27(3):806-819 . PubMed
  79. Wu M, et al. 2021. Nat Commun. 12:3500. PubMed
  80. Fu Y, et al. 2020. Mol Ther. 1214:28. PubMed
  81. Altshuler A, et al. 2021. Cell Stem Cell. 28(7):1248-1261.e8. PubMed
  82. Tang Y, et al. 2020. Front Immunol. 11:585918. PubMed
  83. Liang Q, et al. 2022. iScience. 25:104043. PubMed
  84. Mirshahi F, et al. 2022. Cell Rep. 38:110454. PubMed
  85. Bangs DJ, et al. 2022. Cell Rep. 38:110266. PubMed
  86. Jazowiecka-Rakus J, et al. 2021. Cancers (Basel). 13:. PubMed
  87. Chen J, et al. 2022. J Nanobiotechnology. 20:283. PubMed
  88. Wu J, et al. 2020. Sci Adv. 6:eaba3458. PubMed
  89. Guan H, et al. 2012. PLoS One. 7:e35650. PubMed
  90. D Kim, S Lee, H Jun 2016. Immunol Cell Biol. 10.1038/icb.2016.98. PubMed
  91. Qi X, et al. 2019. Nat Commun. 10:2141. PubMed
  92. He C, et al. 2020. Clin Transl Med. 10:e39. PubMed
  93. Molina-Sanchez P, et al. 2020. Gastroenterology. 2203:159. PubMed
  94. Brooks JF, et al. 2020. Cytotherapy. 22:436. PubMed
  95. Aqel SI, et al. 2021. JCI Insight. 6:e142376. PubMed
  96. Hu D, et al. 2021. J Cell Mol Med. 25:2900. PubMed
  97. Shi S, et al. 2020. Clin Cancer Res. 26:5990. PubMed
  98. Wang Y, et al. 2022. Acta Pharm Sin B. 12:262. PubMed
  99. Zhou HF, et al. 2022. Front Pharmacol. 13:778755. PubMed
  100. Liang Z, et al. 2021. J Cell Physiol. 236:4725. PubMed
  101. Mardomi A, et al. 2021. J Cell Physiol. 236:6328. PubMed
  102. Xu F, et al. 2022. Cell Death Discov. 8:142. PubMed
  103. Sarapulov AV, et al. 2020. Front Immunol. 11:599. PubMed
  104. White C, et al. 2014. J Immunol. 193:5933. PubMed
  105. Thomas S, et al. 2019. J Immunother Cancer. 7:214. PubMed
  106. Tritama E, et al. 2018. Hum Vaccin Immunother. 14:1524. PubMed
  107. Li H, et al. 2021. Nat Commun. 12:2773. PubMed
  108. Jiang S, et al. 2020. Scand J Immunol. e12867:91. PubMed
  109. Mitchell JE, et al. 2021. Cell Reports. 35(2):108966. PubMed
  110. Mauduit O, et al. 2022. Front Immunol. 13:1011125. PubMed
  111. Liu Y, et al. 2022. Nat Commun. 13:2665. PubMed
  112. Anastasiou M, et al. 2021. JCI Insight. 6:. PubMed
  113. Zongyi Y, et al. 2017. PLoS One. 10.1371/journal.pone.0189617. PubMed
  114. Ma X, et al. 2021. Cell Metabolism. 33(5):1001-1012.e5. PubMed
  115. Cheng K, et al. 2021. Nat Commun. 12:2041. PubMed
  116. Ren HZ, et al. 2022. J Clin Transl Hepatol. 10:1138. PubMed
  117. Edwards CJ, et al. 2021. Br J Cancer. . PubMed
  118. Jing L, et al. 2022. Front Immunol. 13:864995. PubMed
  119. Feng H, et al. 2020. J Dermatol. 47:147. PubMed
  120. Pedraza–Zamora CP, et al. 2017. Parasite Immunol. 39:4. PubMed
  121. Chen L, et al. 2021. Cell Death Differ. 28:1880. PubMed
  122. Wang Z, et al. 2020. J Clin Invest. 130:3717. PubMed
  123. Raineri D, et al. 2021. Biomedicines. 10:. PubMed
  124. He X, et al. 2021. Small. 17:e2007165. PubMed
  125. Katsinas N, et al. 2022. J Clin Med. 11:. PubMed
  126. He X, et al. 2021. Adv Sci (Weinh). 8:e2103023. PubMed
  127. Cervera–Carrascon V, et al. 2020. Oncoimmunology. 9:1761229. PubMed
  128. Paul S, et al. 2018. Appl Microbiol Biotechnol. 102:8895. PubMed
  129. Vigeland C, et al. 2016. PLoS One. 11: 0163288. PubMed
  130. Lu X, et al. 2016. Nat Commun. 7: 12719. PubMed
  131. Zhang W, et al. 2019. Oncol Lett. 17:815. PubMed
  132. Deng Z, et al. 2020. World J Gastrointest Oncol. 1091:12. PubMed
  133. Cheng B, et al. 2022. Cancer Commun (Lond). 42:17. PubMed
  134. Wang Z, et al. 2022. Nat Biomed Eng. 6:791. PubMed
  135. Guo P, et al. 2021. J Immunol. 207:408. PubMed
  136. Knocke S, et al. 2016. Cell Rep. 17:2234-2246. PubMed
  137. Ahmari N, et al. 2016. Physiol Genomics. 48: 526 - 536. PubMed
  138. Ito C, et al. 2015. PLoS One. 10: e0140808. PubMed
  139. Dmitrieva‐Posocco O et al. 2019. Immunity. 50(1):166-180 . PubMed
  140. Kim JH, et al. 2019. Mol Med. 25:33. PubMed
  141. Niknam S, et al. 2018. Clin Cancer Res. 24:5735. PubMed
  142. Habib S, et al. 2018. Infect Immun. 86:e00019. PubMed
  143. Volberding PJ, et al. 2021. Cell Reports. 35(8):109160. PubMed
  144. Zhao X, et al. 2022. Nat Protoc. 17:2240. PubMed
  145. Zhou H, et al. 2022. Oncoimmunology. 11:2057892. PubMed
  146. He X, et al. 2022. Cancer Immunol Res. 10:314. PubMed
  147. Hum NR, et al. 2022. Front Oncol. 12:928474. PubMed
  148. Zeng Q, et al. 2022. Front Immunol. 13:740805. PubMed
  149. Zuo S, et al. 2021. J Immunother Cancer. 9:. PubMed
  150. Zhang Y, et al. 2021. J Immunol Res. 2021:5599439. PubMed
  151. Zhang H, et al. 2019. Mol Cell. 76:110. PubMed
  152. Uddback I, et al. 2016. Sci Rep. 6:20137. PubMed
  153. Toomer K, et al. 2016. J Immunol. 196: 3665 - 3676. PubMed
  154. Faust HJ, et al. 2020. J Clin Invest. 130:5493. PubMed
  155. Kruta M, et al. 2021. Cell Stem Cell. :. PubMed
  156. Haas MS, et al. 2020. Mol Cancer Res. 19:717. PubMed
  157. Zhu Y, et al. 2021. EMBO J. 40:e105320. PubMed
  158. Wang Y, et al. 2021. Front Microbiol. 12:701566. PubMed
  159. Gebre MS, et al. 2022. NPJ Vaccines. 7:88. PubMed
  160. Yang B, et al. 2022. Bioengineered. 13:2685. PubMed
  161. Mencl S, et al. 2014. J Neuroimmunol. 274:125. PubMed
  162. Zhou J, et al. 2019. Nat Commun. 10:2427. PubMed
  163. Lu J, et al. 2021. Cell Death Discov. 7:165. PubMed
  164. Han F, et al. 2020. Invest Ophthalmol Vis Sci. 61:24. PubMed
  165. Yan J, et al. 2020. Cell Rep. 107820:31. PubMed
  166. Shannon JP, et al. 2021. Immunity. 54(2):276-290.e5. PubMed
  167. Sun H, et al. 2022. Front Immunol. 13:818017. PubMed
  168. Frost JN, et al. 2021. Med (N Y). 2:164. PubMed
  169. Ding P, et al. 2022. Bone Res. 10:42. PubMed
  170. Lang V, et al. 2021. Elife. 10:. PubMed
  171. Peng L, et al. 2022. Cell Rep Med. 3:100634. PubMed
  172. Huang L, et al. 2021. Breast Cancer Res Treat. Online ahead of print. PubMed
  173. Tao Z, et al. 2019. Clin Cancer Res. 25:1113. PubMed
  174. Kmieciak M, et al. 2011. J Vis Exp. 47: 2381. PubMed
  175. Li Y, Kaneda T 2016. Sci Rep. 6: 25077. PubMed
  176. Subramanian K, et al. 2019. Nat Microbiol. 4:62. PubMed
  177. Yang BH, et al. 2020. Cell Reports. 27(12):3629-3645.e6.. PubMed
  178. Timilshina M, et al. 2017. PLoS One. 10.1371/journal.pone.0168942. PubMed
  179. Wang X, et al. 2020. Nat Commun. 4.505555556. PubMed
  180. Wei Z, et al. 2021. Nat Commun. 0.805555556. PubMed
  181. Zhang Q, et al. 2021. Front Cell Dev Biol. 9:655552. PubMed
  182. Zeng Q, et al. 2022. iScience. 25:105151. PubMed
  183. Guo S, et al. 2021. Sci Rep. 11:23745. PubMed
  184. Ma K, et al. 2022. iScience. 25:104347. PubMed
  185. Li J, et al. 2022. Nat Commun. 13:4032. PubMed
  186. Gao X, et al. 2022. Front Immunol. 13:799331. PubMed
  187. Kamata T, et al. 2020. Cell Reports. 31(12):107802. PubMed
  188. Ouyang S, et al. 2019. J Immunol. 202:1441. PubMed
  189. Reynolds CJ, et al. 2018. Sci Rep. 8:672. PubMed
  190. Nasarre P, et al. 2021. Cancers (Basel). 13: . PubMed
  191. Wang Y, et al. 2020. Virol Sin. 36:122. PubMed
  192. Liu Y, et al. 2020. Oncol Lett. 2369:20. PubMed
  193. Martomo SA, et al. 2021. Mol Cancer Ther. 1.074305556. PubMed
  194. Zan H, et al. 2017. Nat Commun. 8:14244. PubMed
  195. Li Z, et al. 2022. Nat Commun. 13:6321. PubMed
  196. He C, et al. 2022. Nat Commun. 13:5459. PubMed
  197. Takaku S, et al. 2022. Evid Based Complement Alternat Med. 2022:6122955. PubMed
  198. Zhang S, et al. 2022. Nat Commun. 13:4744. PubMed
  199. Yuan M, et al. 2022. Oxid Med Cell Longev. 2022:5479491. PubMed
  200. Li J, et al. 2020. Development. :. PubMed
  201. Shibuya M, et al. 2021. iScience. 24:103131. PubMed
  202. Liu YG, et al. 2019. FASEB J. 33:5018. PubMed
  203. Yao C, et al. 2018. Autophagy. 1.854861111. PubMed
  204. Nechama M, et al. 2018. Nat Commun. 9:1603. PubMed
  205. Xia Y, et al. 2018. Cell. 175:1059. PubMed
  206. Ligon MM, et al. 2020. Mucosal Immunol. 1.172222222. PubMed
  207. Da Mesquita S, et al. 2021. Science Advances. 7(21):. PubMed
  208. Wedekind MF, et al. 2021. iScience. 24(7):102759. PubMed
  209. Karanika S, et al. 2022. Front Immunol. 13:972266. PubMed
  210. Zhang Q, et al. 2022. Commun Biol. 5:544. PubMed
  211. Jazowiecka-Rakus J, et al. 2020. Mol Ther Oncolytics. 18:335. PubMed
  212. Soria-Castro R, et al. 2020. Sci Rep. 10:17802. PubMed
  213. Chen H, et al. 2022. Front Pharmacol. 13:827520. PubMed
  214. Khosravi N, et al. 2018. Cancer Immunol Res. 0.797222222. PubMed
  215. Kos S, et al. 2019. PLoS One. 14:e0217762. PubMed
  216. Ji L et al. 2019. Immunity. 51(2):272-284 . PubMed
  217. Habtetsion T et al. 2018. Cell metabolism. 28(2):228-242 . PubMed
  218. Coley WD et al. 2018. F1000Research. 2018 Mar 14 [revised 2018 Jan 1] 0.5125. PubMed
  219. Liu Y, et al. 2020. Cell Death Dis. 11:1062. PubMed
  220. Si J, et al. 2020. Cancer Cell. 38(4):551-566.e11. PubMed
  221. Pan L, et al. 2022. Front Immunol. 13:837497. PubMed
  222. Zheng Y, et al. 2022. J Immunol. 208:501. PubMed
  223. He X, et al. 2021. J Immunother Cancer. 9:. PubMed
  224. Zhou H, et al. 2021. Cell Death Discov. 7:332. PubMed
  225. Sivapatham S, et al. 2019. Front Immunol. 1.865277778. PubMed
  226. Zhao Y, et al. 2020. Front Immunol. 2.572222222. PubMed
  227. Bryan Hart, Sunhee Lee 2016. PLoS Negl Trop Dis. 10:e0005229. PubMed
  228. Golan K et al. 2018. Cell stem cell. 23(4):572-585 . PubMed
  229. Blaszczak AM, et al. 2020. Immunometabolism. 2:00. PubMed
  230. Yang C, et al. 2020. Cell Host Microbe. 467:27. PubMed
  231. Sears SM, et al. 2022. Kidney360. 3:818. PubMed
  232. Sun F, et al. 2022. Cell Death Dis. 13:181. PubMed
  233. Zhong C, et al. 2021. J Virol. 95:e0092521. PubMed
  234. Magee JA, et al. 2021. Stem Cell Reports. 16:20. PubMed
  235. Xu Y, et al. 2021. iScience. 24:103445. PubMed
  236. Zhou S, et al. 2021. Adv Funct Mater. 31:. PubMed
  237. Smith KJ, et al. 2022. PLoS Biol. 20:e3001554. PubMed
  238. Ramanan D, et al. 2020. Cell. 181(6):1276-1290. PubMed
  239. Hidalgo San Jose L, et al. 2020. Cell Rep. 30:69. PubMed
  240. Hart B, et al. 2015. PLoS Negl Trop Dis. 9: 0004046. PubMed
  241. Blaszczak AM, et al. 2019. J Immunol. 202:2451. PubMed
  242. Liang Z, et al. 2017. Autophagy. 14:505. PubMed
  243. Aguilera TA, et al. 2020. Clin Cancer Res. 26:2972. PubMed
  244. Simoni L, et al. 2020. Cell Rep. 33:108330. PubMed
  245. Nakao R, et al. 2022. NPJ Vaccines. 7:153. PubMed
  246. Wang Y, et al. 2022. Nat Commun. 13:1454. PubMed
  247. Barsoumian HB, et al. 2022. Cancers (Basel). 14:. PubMed
  248. Chen YL, et al. 2022. Front Neurosci. 16:876582. PubMed
  249. Li Z, et al. 2022. Evid Based Complement Alternat Med. 2022:7421265. PubMed
  250. Yue T, et al. 2022. Cell Death Differ. 29:218. PubMed
  251. Hong Y, et al. 2019. J Extracell Vesicles. 8:1670893. PubMed
  252. Angela M, et al. 2016. Nat Commun. 7:13683. PubMed
  253. Bartley A, et al. 2018. Front Physiol. 9:1593. PubMed
  254. Timilshina M, et al. 2020. Cell Reports. 27(10):2948-2961.e7.. PubMed
  255. Gardenier J, et al. 2017. Nat Commun. 8:14345. PubMed
  256. Jaeger N, et al. 2020. Cell Rep. 33:108331. PubMed
  257. Zeng A, et al. 2020. Oncol Rep. . PubMed
  258. Hsu HP, et al. 2021. J Biol Chem. 296:100419. PubMed
  259. Zhang M, et al. 2022. iScience. 25:104490. PubMed
  260. Chen Y, et al. 2021. Braz J Med Biol Res. 54:e9570. PubMed
  261. Rodrigues KA, et al. 2021. Sci Adv. 7:eabj6538. PubMed
  262. Kathania M, et al. 2022. Cell Rep. 40:111345. PubMed
  263. Gawish R, et al. 2022. Elife. 11:. PubMed
  264. Li J, et al. 2022. Nat Commun. 13:1481. PubMed
  265. Zhou T, et al. 2018. Mol Med Rep. 17:4883. PubMed
  266. Ding X, et al. 2021. Front Immunol. 12:667136. PubMed
  267. Guo S, et al. 2021. Frontiers in Immunology. 11:614667. PubMed
  268. Cortez MA, et al. 2020. Nat Commun. 3.819444444. PubMed
  269. Li CY, et al. 2022. Int J Mol Sci. 23:. PubMed
  270. Liang Z, et al. 2022. iScience. 25:105233. PubMed
  271. Lestari SR, et al. 2020. J Ayurveda Integr Med. 11:414. PubMed
  272. Jiang W, et al. 2021. Cell Rep. 37:110112. PubMed
  273. Chang MH, et al. 2021. Cell Rep. 37:109902. PubMed
RRID
AB_312690 (BioLegend Cat. No. 100405)
AB_312691 (BioLegend Cat. No. 100406)

Antigen Details

Structure
Ig superfamily, 55 kD
Distribution

Majority of thymocytes, T cell subset

Function
TCR co-receptor, T cell activation
Ligand/Receptor
MHC class II molecule
Cell Type
Dendritic cells, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Bierer BE, et al. 1989. Annu. Rev. Immunol. 7:579.
3. Janeway CA. 1992. Annu. Rev. Immunol. 10:645.

Gene ID
12504 View all products for this Gene ID
Specificity (DOES NOT SHOW ON TDS):
CD4
Specificity Alt (DOES NOT SHOW ON TDS):
CD4
App Abbreviation (DOES NOT SHOW ON TDS):
FC
Hidden Names (DOES NOT SHOW ON TDS):
Myeloid Dendritic Cell, Naïve T Cell, Plasmacytoid Dendritic Cell, T Follicular Helper, Th1, Th2, Th9, Th17, Th22, Treg
UniProt
View information about CD4 on UniProt.org

Related FAQs

I am unable to see expression of T cell markers such as CD3 and CD4 post activation.
TCR-CD3 complexes on the T-lymphocyte surface are rapidly downregulated upon activation with peptide-MHC complex, superantigen or cross-linking with anti-TCR or anti-CD3 antibodies. PMA/Ionomycin treatment has been shown to downregulate surface CD4 expression. Receptor downregulation is a common biological phenomenon and so make sure that your stimulation treatment is not causing it in your sample type.

Other Formats

View All CD4 Reagents Request Custom Conjugation
Description Clone Applications
PE/Cyanine7 anti-mouse CD4 GK1.5 FC
APC/Cyanine7 anti-mouse CD4 GK1.5 FC
Brilliant Violet 711™ anti-mouse CD4 GK1.5 FC
Brilliant Violet 510™ anti-mouse CD4 GK1.5 FC
Brilliant Violet 605™ anti-mouse CD4 GK1.5 FC
Brilliant Violet 785™ anti-mouse CD4 GK1.5 FC
PE/Dazzle™ 594 anti-mouse CD4 GK1.5 FC
APC/Fire™ 750 anti-mouse CD4 GK1.5 FC
GoInVivo™ Purified anti-mouse CD4 GK1.5 FC
Brilliant Violet 750™ anti-mouse CD4 GK1.5 FC
Brilliant Violet 650™ anti-mouse CD4 GK1.5 FC
Spark Blue™ 550 anti-mouse CD4 GK1.5 FC
Spark NIR™ 685 anti-mouse CD4 GK1.5 FC
KIRAVIA Blue 520™ anti-mouse CD4 GK1.5 FC
PE/Fire™ 640 anti-mouse CD4 GK1.5 FC
APC/Fire™ 810 anti-mouse CD4 GK1.5 FC
PE/Fire™ 700 anti-mouse CD4 GK1.5 FC
APC anti-mouse CD4 GK1.5 FC
Biotin anti-mouse CD4 GK1.5 FC,IHC-F,ICC
FITC anti-mouse CD4 GK1.5 FC
PE anti-mouse CD4 GK1.5 FC
PE/Cyanine5 anti-mouse CD4 GK1.5 FC
Purified anti-mouse CD4 GK1.5 FC,IHC-F,ICC,IP,Costim,Block,Depletion
Alexa Fluor® 647 anti-mouse CD4 GK1.5 FC,IHC-F
Alexa Fluor® 488 anti-mouse CD4 GK1.5 FC,IHC-F
Pacific Blue™ anti-mouse CD4 GK1.5 FC
Alexa Fluor® 700 anti-mouse CD4 GK1.5 FC
PerCP anti-mouse CD4 GK1.5 FC
PerCP/Cyanine5.5 anti-mouse CD4 GK1.5 FC
Brilliant Violet 421™ anti-mouse CD4 GK1.5 FC,ICC,IHC-F
Ultra-LEAF™ Purified anti-mouse CD4 GK1.5 FC,Block,Costim,Depletion,IHC,IP
Alexa Fluor® 594 anti-mouse CD4 GK1.5 IHC-F,FC,SB
Spark Violet™ 538 anti-mouse CD4 GK1.5 FC
Spark YG™ 593 anti-mouse CD4 GK1.5 FC
Spark Blue™ 574 anti-mouse CD4 Antibody GK1.5 FC
Spark UV™ 387 anti-mouse CD4 GK1.5 FC
Spark Blue™ 515 anti-mouse CD4 GK1.5 FC
Spark PLUS UV395™ anti-mouse CD4 GK1.5 FC
Spark Red™ 718 anti-mouse CD4 (Flexi-Fluor™) GK1.5 FC
PerCP/Fire™ 806 anti-mouse CD4 Antibody GK1.5 FC
PerCP/Fire™ 780 anti-mouse CD4 Antibody GK1.5 FC
Spark YG™ 581 anti-mouse CD4 (Flexi-Fluor™) GK1.5 FC
StarBright UltraViolet 795 anti-mouse CD4 GK1.5 FC
Spark PLUS V475™ anti-mouse CD4 GK1.5 FC
Spark PLUS B488™ anti-mouse CD4 GK1.5 FC
PE/Fire™ 744 anti-mouse CD4 GK1.5 FC
Spark PLUS YG581™ anti-mouse CD4 GK1.5 FC
Go To Top Version: 1    Revision Date: 11/30/2012

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account